- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07949474
Semaglutide in Alcohol Use Disorder
A 45-week, Randomized, Controlled Trial of Semaglutide on Alcohol Related Outcomes in Adults With Alcohol Use Disorder and Obesity
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes (alcohol intake, cravings, self-control, affect, quality of life, physiologic data; collected using validated questionnaires and in one's natural environments using ecological momentary assessment (EMA) and wearable devices [i.e., activity/health trackers]) among 128 adults (18 to 65 years old) with alcohol use disorder (AUD) and obesity (body mass index (BMI) >/= 30). We also seek to develop personal causal models for alcohol use and urges.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Eric Bomberg, MD
- Telefonnummer: (612) 626-2349
- E-post: bombe002@umn.edu
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55414
- University of Minnesota Center for Pediatric Obesity Medicine
-
Ta kontakt med:
- Eric Bomberg, MD
- Telefonnummer: (612) 626-2349
- E-post: bombe002@umn.edu
-
Hovedetterforsker:
- Eric Bomberg, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-65 years
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for mild or moderate AUD
- >/=1 bout of heavy drinking (defined as >/= 4 drinks/day for females; >/= 5 drinks/day for males) within the last month
- Have an interest in reducing or quitting alcohol intake
- Have obesity (defined as BMI >/= 30 kg/m2) at screening
- Ability to provide informed consent before any trial-related activities
Exclusion Criteria:
- Impaired ability to provide consent to a clinical trial and/or comply with study procedures and/or measures using a smartphone (e.g., intellectual disability, acute intoxication, etc.)
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for Severe AUD
- Lifetime diagnosis of psychosis and/or bipolar-spectrum disorders
- Serious withdrawal symptoms defined as a score higher than 9 on Clinical Institute Withdrawal Assessment (CIWA) for Alcohol Scale, Revised at the baseline visit
- Current or history of neurological disease including traumatic brain injury
- Diagnosis of type 1 diabetes mellitus
- Diagnosis of type 2 diabetes mellitus with A1c >/= 10% or type 2 diabetes mellitus on insulin therapy
- Current hyperthyroidism or uncontrolled hypothyroidism
- Current pregnancy or breast-feeding, plans to become pregnant within the next 12 months, or if sexually active refusal to use adequate contraceptive measures
- Impaired hepatic function (aspartate aminotransferase (AST)or alanine aminotransferase (ALT) > 3 times upper normal limit
- Impaired renal function (estimated glomerular filtration rate (eGFR)< 50 mL/minute
- Known hypersensitivity to semaglutide
- Any history of pancreatitis (acute or chronic; contraindication for semaglutide)
- Triglycerides >/= 1000 mg/dL
- History of medullary thyroid carcinoma (MTC) and/or family history with MTC and/or multiple endocrine neoplasia syndrome type 2 (contraindication for semaglutide)
- Uncontrolled hypertension (systolic blood pressure > 180 mm Hg; diastolic blood pressure > 110 mm Hg)
- Concomitant pharmacotherapy for alcohol dependence (e.g. disulfiram, naltrexone, acamprosate) or treatment with any of these within 1 month prior to screening visit
- Current or recent (< 6 months prior to screening) use of weight loss medication(s) (e.g., phentermine, Glucagon-Like Peptide-1 Receptor Agonist (GLP1-RAs)) or other weight altering medication(s) (e.g., atypical anti-psychotics), unless dose(s) of these have been stable for >6 months from screening
- Any condition that the investigator feels would interfere with trial participation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Semaglutide
Participants in this arm of the study will receive semaglutide (the study drug) |
Participants in this arm will receive 42 weeks of treatment with semaglutide |
|
Placebo komparator: Placebo
Participants in this arm will receive placebo |
Participants in this arm will receive 42 weeks of placebo |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Heavy drinking days
Tidsramme: Randomization to Week 45
|
Number of heavy drinking days |
Randomization to Week 45
|
|
Total drinking days
Tidsramme: Randomization to Week 45
|
Total number of drinking days |
Randomization to Week 45
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Eric Bomberg, MD, University of Minnesota
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PEDS-2026-35422
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified study data will be shared upon completion of a data use agreement
IPD-delingstidsramme
April 30, 2033 (start date) April 30, 2037 (end date)
Tilgangskriterier for IPD-deling
Interested parties should contact Dr. Bomberg to start the process of starting a data use agreement
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .